The intact strontium ranelate complex stimulates osteoblastogenesis and suppresses osteoclastogenesis by antagonizing NF-κB activation
- 27 August 2011
- journal article
- research article
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 359 (1-2) , 399-407
Abstract
Strontium ranelate, a pharmaceutical agent shown in clinical trials to be effective in managing osteoporosis and reducing fracture risk in postmenopausal women, is relatively unique in its ability to both blunt bone resorption and stimulate bone formation. However, its mechanisms of action are largely unknown. As the nuclear factor-kappa B (NF-κB) activation antagonists both stimulate osteoblastic bone formation and repress osteoclastic bone resorption, we hypothesized that strontium ranelate may achieve its anabolic and anti-catabolic activities by modulating NF-κB activation in bone cells. In this study, osteoclast and osteoblast precursors were treated with intact strontium ranelate or its individual components sodium ranelate and/or strontium chloride, and its effect on in vitro osteoclastogenesis and osteoblastogenesis and on NF-κB activation quantified. Although the activity of strontium ranelate has been attributed to the release of strontium ions, low dose intact strontium ranelate complex, but not sodium ranelate and/or strontium chloride, potently antagonized NF-κB activation in osteoclasts and osteoblasts in vitro, and promoted osteoblast differentiation while suppressing osteoclast formation. Taken together, our data suggest a novel centralized mechanism by which strontium ranelate promotes osteoblast activity and suppresses osteoclastogenesis, based on suppression of NF-κB signal transduction. We further demonstrate that the biological actions of strontium ranelate may be related to low dose of the intact molecule rather than dissociation and release of strontium ions, as previously thought. These data may facilitate the development of additional novel pharmacological agents for the amelioration of osteoporosis, based on NF-κB blockade.Keywords
This publication has 30 references indexed in Scilit:
- Strontium Ranelate Decreases Receptor Activator of Nuclear Factor-κB Ligand-Induced Osteoclastic Differentiation In Vitro: Involvement of the Calcium-Sensing ReceptorMolecular Pharmacology, 2010
- The Calcium-sensing Receptor (CaR) is Involved in Strontium Ranelate-induced Osteoblast Differentiation and MineralizationHormone and Metabolic Research, 2010
- The bone anabolic carotenoid β-cryptoxanthin enhances transforming growth factor-β1-induced SMAD activation in MC3T3 preosteoblastsInternational Journal of Molecular Medicine, 2009
- Molecular Mechanism of the Bifunctional Role of Lipopolysaccharide in OsteoclastogenesisJournal of Biological Chemistry, 2009
- Ubiquitin Ligase Smurf1 Mediates Tumor Necrosis Factor-induced Systemic Bone Loss by Promoting Proteasomal Degradation of Bone Morphogenetic Signaling ProteinsJournal of Biological Chemistry, 2008
- RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in miceJournal of Clinical Investigation, 2008
- Induction of a program gene expression during osteoblast differentiation with strontium ranelateBiochemical and Biophysical Research Communications, 2007
- Transforming Growth Factor-β1 to the BoneEndocrine Reviews, 2005
- In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiationEuropean Journal of Pharmacology, 2002
- Osteopetrosis in mice lacking NF-κB1 and NF-κB2Nature Medicine, 1997